Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1995 Nov;96(5):2503–2509. doi: 10.1172/JCI118310

Production, characterization, and expression of neuropeptide Y by human pheochromocytoma.

P deS Senanayake 1, J Denker 1, E L Bravo 1, R M Graham 1
PMCID: PMC185905  PMID: 7593641

Abstract

Neuropeptide Y (NPY) levels are increased in plasma and tumors of patients with pheochromocytoma. The present study was designed to evaluate plasma and tissue NPY levels simultaneously as well as to study its release and expression in patients with either adrenal or extraadrenal pheochromocytomas. Plasma NPY levels were higher (P < 0.01) in patients with adrenal tumors than in matched normal subjects and patients with extraadrenal tumors. NPY levels were also higher (P < 0.05) in adrenal than in extraadrenal tumors. Bioactive NPY (1-36) was the predominant form in plasma and tumors of patients with adrenal pheochromocytomas. In contrast, patients with extraadrenal pheochromocytomas had an abundance of NPY fragments. NPY mRNA was abundant in 11 of 13 adrenal tumors but in only 1 of 6 extraadrenal tumors. Moreover, NPY was coreleased with NE with manipulation of adrenal but not extraadrenal tumors. These findings indicate that increased NPY gene expression in adrenal pheochromocytomas accounts for the greater biosynthesis and storage of NPY in these tumors and that increased release of NPY results in elevated plasma NPY. Factors regulating NPY gene expression in pheochromocytoma and the role of NPY in the clinical manifestations of the disease remain to be elucidated.

Full text

PDF
2503

Images in this article

2507Image
on p.2507
2507Image
on p.2507
2507Image
on p.2507

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aakerlund L., Gether U., Fuhlendorff J., Schwartz T. W., Thastrup O. Y1 receptors for neuropeptide Y are coupled to mobilization of intracellular calcium and inhibition of adenylate cyclase. FEBS Lett. 1990 Jan 15;260(1):73–78. doi: 10.1016/0014-5793(90)80069-u. [DOI] [PubMed] [Google Scholar]
  2. Adrian T. E., Allen J. M., Terenghi G., Bacarese-Hamilton A. J., Brown M. J., Polak J. M., Bloom S. R. Neuropeptide Y in phaeochromocytomas and ganglioneuroblastomas. Lancet. 1983 Sep 3;2(8349):540–542. doi: 10.1016/s0140-6736(83)90570-6. [DOI] [PubMed] [Google Scholar]
  3. Allen J. M., Tischler A. S., Lee Y. C., Bloom S. R. Neuropeptide Y (NPY) in PC12 phaeochromocytoma cultures: responses to dexamethasone and nerve growth factor. Neurosci Lett. 1984 May 18;46(3):291–296. doi: 10.1016/0304-3940(84)90114-9. [DOI] [PubMed] [Google Scholar]
  4. Allen J. M., Yeats J. C., Adrian T. E., Bloom S. R. Radioimmunoassay of neuropeptide Y. Regul Pept. 1984 Jan;8(1):61–70. doi: 10.1016/0167-0115(84)90029-6. [DOI] [PubMed] [Google Scholar]
  5. Azizi M., Day M., Plouin P. F. Localizing value of catecholamine profile in patients with adrenal or ectopic pheochromocytoma. Am J Hypertens. 1994 Jan;7(1):110–111. doi: 10.1093/ajh/7.1.110. [DOI] [PubMed] [Google Scholar]
  6. Bravo E. L., Tarazi R. C., Gifford R. W., Stewart B. H. Circulating and urinary catecholamines in pheochromocytoma. Diagnostic and pathophysiologic implications. N Engl J Med. 1979 Sep 27;301(13):682–686. doi: 10.1056/NEJM197909273011302. [DOI] [PubMed] [Google Scholar]
  7. Brown M. R., Allen R., Fisher L. A. Assessment of peptide regulation of the autonomic nervous system. Methods Enzymol. 1989;168:431–443. doi: 10.1016/0076-6879(89)68034-2. [DOI] [PubMed] [Google Scholar]
  8. Chirgwin J. M., Przybyla A. E., MacDonald R. J., Rutter W. J. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 1979 Nov 27;18(24):5294–5299. doi: 10.1021/bi00591a005. [DOI] [PubMed] [Google Scholar]
  9. Corder R., Emson P. C., Lowry P. J. Purification and characterization of human neuropeptide Y from adrenal-medullary phaeochromocytoma tissue. Biochem J. 1984 May 1;219(3):699–706. doi: 10.1042/bj2190699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Creutzfeldt W., Arnold R., Creutzfeldt C., Deuticke U., Frerichs H., Track N. S. Biochemical and morphological investigations of 30 human insulinomas. Correlation between the tumour content of insulin and proinsulin-like components and the histological and ultrastructural appearance. Diabetologia. 1973 Jun;9(3):217–231. doi: 10.1007/BF01219786. [DOI] [PubMed] [Google Scholar]
  11. De Potter W. P., Dillen L., Annaert W., Tombeur K., Berghmans R., Coen E. P. Evidence for the co-storage and co-release of neuropeptide Y and noradrenaline from large dense cored vesicles in sympathetic nerves of the bovine vas deferens. Synapse. 1988;2(2):157–162. doi: 10.1002/syn.890020207. [DOI] [PubMed] [Google Scholar]
  12. Ekblad E., Edvinsson L., Wahlestedt C., Uddman R., Håkanson R., Sundler F. Neuropeptide Y co-exists and co-operates with noradrenaline in perivascular nerve fibers. Regul Pept. 1984 Apr;8(3):225–235. doi: 10.1016/0167-0115(84)90064-8. [DOI] [PubMed] [Google Scholar]
  13. Greene L. A., Tischler A. S. Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci U S A. 1976 Jul;73(7):2424–2428. doi: 10.1073/pnas.73.7.2424. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Grouzmann E., Werffeli-George P., Fathi M., Burnier M., Waeber B., Waeber G. Angiotensin-II mediates norepinephrine and neuropeptide-Y secretion in a human pheochromocytoma. J Clin Endocrinol Metab. 1994 Dec;79(6):1852–1856. doi: 10.1210/jcem.79.6.7989494. [DOI] [PubMed] [Google Scholar]
  15. Helman L. J., Cohen P. S., Averbuch S. D., Cooper M. J., Keiser H. R., Israel M. A. Neuropeptide Y expression distinguishes malignant from benign pheochromocytoma. J Clin Oncol. 1989 Nov;7(11):1720–1725. doi: 10.1200/JCO.1989.7.11.1720. [DOI] [PubMed] [Google Scholar]
  16. Herzog H., Hort Y. J., Ball H. J., Hayes G., Shine J., Selbie L. A. Cloned human neuropeptide Y receptor couples to two different second messenger systems. Proc Natl Acad Sci U S A. 1992 Jul 1;89(13):5794–5798. doi: 10.1073/pnas.89.13.5794. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Higuchi H., Iwasa A., Yokokawa K. High levels of expression of neuropeptide Y mRNA in human phaeochromocytomas. Clin Exp Pharmacol Physiol. 1994 May;21(5):359–365. doi: 10.1111/j.1440-1681.1994.tb02528.x. [DOI] [PubMed] [Google Scholar]
  18. Higuchi H., Yang H. Y., Sabol S. L. Rat neuropeptide Y precursor gene expression. mRNA structure, tissue distribution, and regulation by glucocorticoids, cyclic AMP, and phorbol ester. J Biol Chem. 1988 May 5;263(13):6288–6295. [PubMed] [Google Scholar]
  19. James S., Burnstock G. Neuropeptide Y-like immunoreactivity in intramural ganglia of the newborn guinea pig urinary bladder. Regul Pept. 1988 Nov;23(2):237–245. doi: 10.1016/0167-0115(88)90031-6. [DOI] [PubMed] [Google Scholar]
  20. Larhammar D., Ericsson A., Persson H. Structure and expression of the rat neuropeptide Y gene. Proc Natl Acad Sci U S A. 1987 Apr;84(7):2068–2072. doi: 10.1073/pnas.84.7.2068. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Lundberg J. M., Hökfelt T., Hemsén A., Theodorsson-Norheim E., Pernow J., Hamberger B., Goldstein M. Neuropeptide Y-like immunoreactivity in adrenaline cells of adrenal medulla and in tumors and plasma of pheochromocytoma patients. Regul Pept. 1986 Jan;13(2):169–182. doi: 10.1016/0167-0115(86)90224-7. [DOI] [PubMed] [Google Scholar]
  22. Lundberg J. M., Tatemoto K. Pancreatic polypeptide family (APP, BPP, NPY and PYY) in relation to sympathetic vasoconstriction resistant to alpha-adrenoceptor blockade. Acta Physiol Scand. 1982 Dec;116(4):393–402. doi: 10.1111/j.1748-1716.1982.tb07157.x. [DOI] [PubMed] [Google Scholar]
  23. Macho P., Pérez R., Huidobro-Toro J. P., Domenech R. J. Neuropeptide Y (NPY): a coronary vasoconstrictor and potentiator of catecholamine-induced coronary constriction. Eur J Pharmacol. 1989 Aug 11;167(1):67–74. doi: 10.1016/0014-2999(89)90748-6. [DOI] [PubMed] [Google Scholar]
  24. Matran R., Martling C. R., Lundberg J. M. Inhibition of cholinergic and non-adrenergic, non-cholinergic bronchoconstriction in the guinea pig mediated by neuropeptide Y and alpha 2-adrenoceptors and opiate receptors. Eur J Pharmacol. 1989 Apr 12;163(1):15–23. doi: 10.1016/0014-2999(89)90390-7. [DOI] [PubMed] [Google Scholar]
  25. Mattiasson A., Ekblad E., Sundler F., Uvelius B. Origin and distribution of neuropeptide Y-, vasoactive intestinal polypeptide-and substance P-containing nerve fibers in the urinary bladder of the rat. Cell Tissue Res. 1985;239(1):141–146. doi: 10.1007/BF00214914. [DOI] [PubMed] [Google Scholar]
  26. Minth C. D., Bloom S. R., Polak J. M., Dixon J. E. Cloning, characterization, and DNA sequence of a human cDNA encoding neuropeptide tyrosine. Proc Natl Acad Sci U S A. 1984 Jul;81(14):4577–4581. doi: 10.1073/pnas.81.14.4577. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. O'Hare M. M., Schwartz T. W. Expression and precursor processing of neuropeptide Y in human pheochromocytoma and neuroblastoma tumors. Cancer Res. 1989 Dec 15;49(24 Pt 1):7010–7014. [PubMed] [Google Scholar]
  28. Pernow J., Ohlén A., Hökfelt T., Nilsson O., Lundberg J. M. Neuropeptide Y: presence in perivascular noradrenergic neurons and vasoconstrictor effects on skeletal muscle blood vessels in experimental animals and man. Regul Pept. 1987 Dec;19(5-6):313–324. doi: 10.1016/0167-0115(87)90173-x. [DOI] [PubMed] [Google Scholar]
  29. Rigby P. W., Dieckmann M., Rhodes C., Berg P. Labeling deoxyribonucleic acid to high specific activity in vitro by nick translation with DNA polymerase I. J Mol Biol. 1977 Jun 15;113(1):237–251. doi: 10.1016/0022-2836(77)90052-3. [DOI] [PubMed] [Google Scholar]
  30. Schwartz T. W. Cellular peptide processing after a single arginyl residue. Studies on the common precursor for pancreatic polypeptide and pancreatic icosapeptide. J Biol Chem. 1987 Apr 15;262(11):5093–5099. [PubMed] [Google Scholar]
  31. Sheikh S. P., Håkanson R., Schwartz T. W. Y1 and Y2 receptors for neuropeptide Y. FEBS Lett. 1989 Mar 13;245(1-2):209–214. doi: 10.1016/0014-5793(89)80223-6. [DOI] [PubMed] [Google Scholar]
  32. Sheikh S. P., O'Hare M. M., Tortora O., Schwartz T. W. Binding of monoiodinated neuropeptide Y to hippocampal membranes and human neuroblastoma cell lines. J Biol Chem. 1989 Apr 25;264(12):6648–6654. [PubMed] [Google Scholar]
  33. Tischler A. S., Allen J. M., Costopoulos D., Bloom S. R. Increased content of neuropeptide Y in human pheochromocytoma cell cultures. J Clin Endocrinol Metab. 1985 Aug;61(2):303–305. doi: 10.1210/jcem-61-2-303. [DOI] [PubMed] [Google Scholar]
  34. Wahlestedt C., Edvinsson L., Ekblad E., Håkanson R. Neuropeptide Y potentiates noradrenaline-evoked vasoconstriction: mode of action. J Pharmacol Exp Ther. 1985 Sep;234(3):735–741. [PubMed] [Google Scholar]
  35. Warner M. R., Levy M. N. Inhibition of cardiac vagal effects by neurally released and exogenous neuropeptide Y. Circ Res. 1989 Dec;65(6):1536–1546. doi: 10.1161/01.res.65.6.1536. [DOI] [PubMed] [Google Scholar]
  36. Warner M. R., Levy M. N. Neuropeptide Y as a putative modulator of the vagal effects on heart rate. Circ Res. 1989 May;64(5):882–889. doi: 10.1161/01.res.64.5.882. [DOI] [PubMed] [Google Scholar]
  37. Westfall T. C., Carpentier S., Chen X., Beinfeld M. C., Naes L., Meldrum M. J. Prejunctional and postjunctional effects of neuropeptide Y at the noradrenergic neuroeffector junction of the perfused mesenteric arterial bed of the rat. J Cardiovasc Pharmacol. 1987 Dec;10(6):716–722. doi: 10.1097/00005344-198712000-00016. [DOI] [PubMed] [Google Scholar]
  38. deS Senanayake P., Warner M. R., Brosnihan K. B., Levy M. N., Ferrario C. M. Circulating neuropeptide Y in dog plasma consists of multiple peptide fragments. Peptides. 1992 Nov-Dec;13(6):1165–1173. doi: 10.1016/0196-9781(92)90024-w. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES